SERPASIL-APRESOLINE
LOE ApproachingNDAORALTABLET
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL-APRESOLINE is a combination oral tablet approved in 1954 containing reserpine and hydralazine for hypertension management. The fixed-dose combination targets blood pressure reduction through dual mechanisms. This is a legacy antihypertensive product with extensive clinical history.
LOE Approaching
With LOE approaching and minimal competitive pressure at 30%, this product is in managed decline mode with likely small, specialized commercial teams focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERPASIL-APRESOLINE offers limited career advancement due to minimal commercial activity and approaching loss of exclusivity. This role is best suited for professionals managing legacy portfolios or seeking stability in a mature product rather than growth-oriented career development.
Brand Manager (legacy products)Field Sales Representative
Worked on SERPASIL-APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.